(E)-N-(4-(2-((2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)vinyl)-3,5-dimethylphenyl)acetamide | 1253917-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: (E)-N-(4-(2-((2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)vinyl)-3,5-dimethylphenyl)acetamide
• 英文别名: N-{4-[(E)-2-(2-cyclohexyl-4-oxo-1,3,8-triaza-spiro[4.5]dec-1-ene-8-sulfonyl)-vinyl]-3,5-dimethyl-phenyl}-acetamide；N-[4-[(E)-2-[(2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl]ethenyl]-3,5-dimethylphenyl]acetamide
• CAS: 1253917-10-0
• 化学式: C₂₅H₃₄N₄O₄S
• 分子量: 486.635
• InChiKey: HGCUAPFZFIXAMW-NTEUORMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (E)-N-(4-(2-((2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)vinyl)-3,5-dimethylphenyl)acetamide 在 20% palladium hydroxide-activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 7.0h， 以78%的产率得到N-(4-(2-((2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)acetamide
  参考文献：
  名称：

  Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

  摘要：

  During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHRl agonist, l-(3,5-dimethyl-4-(2-((2-((lR,4R)-4-methylcyclohexyl)-4-oxo-l,3,8-triazaspiro[4.5]dec-l-en-8-yl)sulfonyl)ethyl)-phenyl)-l-methylurea (CH5447240, 141). Compound 141 exhibited a potent in vitro hPTHRl agonist effect with EC20 of 3.0 mu M and EC50 of 12 mu M and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes. Importantly, 141 showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.

  DOI：

  10.1021/acs.jmedchem.8b00182
• 作为产物：
  描述：

  4-氨基-4-氰基-哌啶-1-羧酸叔丁酯 在 盐酸 、 4-二甲氨基吡啶 、 N-甲基二环己基胺 、 双氧水 、 三乙胺 、 sodium hydroxide 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 9.5h， 生成 (E)-N-(4-(2-((2-cyclohexyl-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)vinyl)-3,5-dimethylphenyl)acetamide
  参考文献：
  名称：

  Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

  摘要：

  During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHRl agonist, l-(3,5-dimethyl-4-(2-((2-((lR,4R)-4-methylcyclohexyl)-4-oxo-l,3,8-triazaspiro[4.5]dec-l-en-8-yl)sulfonyl)ethyl)-phenyl)-l-methylurea (CH5447240, 141). Compound 141 exhibited a potent in vitro hPTHRl agonist effect with EC20 of 3.0 mu M and EC50 of 12 mu M and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes. Importantly, 141 showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.

  DOI：

  10.1021/acs.jmedchem.8b00182

文献信息

• Spiroimidazolone derivative
  申请人：Esaki Toru

  公开号：US09169254B2

  公开（公告）日：2015-10-27

  The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

  本发明涉及一种由以下式(1)表示的化合物：其中W、X、Y、R1、R2、R33、R34、m和n如权利要求中所定义，或其药学上可接受的盐。
• SPIROIMIDAZOLONE DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2433940B9

  公开（公告）日：2015-10-28
• US9169254B2
  申请人：——

  公开号：US9169254B2

  公开（公告）日：2015-10-27
• US9487517B2
  申请人：——

  公开号：US9487517B2

  公开（公告）日：2016-11-08